DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Ocumetics Technology (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) president and CEO Dean Burns discusses the company’s plans to embark on its first in-human study for its Ocumetics lens technology or AOL.
00:00 Introduction
00:46 Highlights of the biocompatibility animal study
02:39 What the animal study sought to achieve
03:43 The Ocumetics Accommodating LenseL technology
06:40 Overview of the company and its leadership team
11:07 Ocumetics’ first-in-human study
14:35 Commercialization timeline
16:35 Ocumetics Technology value proposition
#biotechnology #biotechstocks #investing
________________________________________________________________
Investing News Network (INN)
Find out more about investing by INN @
https://investingnews.com/
Browse our 2023 outlook reports:
http://bit.ly/3JHyR1M
Follow us Facebook:
https://www.facebook.com/investing.news.your.trusted.source
Follow us on Twitter:
@INN_Lifescience
________________________________________________________________
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
